Clinical Trials- Prostate

 TITLE

 PHASE

 CONTACT

 LOCATION

Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAk-700 for Men with High Risk Prostate Cancer (RTOG 1115)

 III

Gladys Pierce RN
gladys.pierce@nmhs.org
402-354-5129

--------------------

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu or

Amy Filler-Katz

 Nebraska Methodist Hospital
Omaha;

Nebraska Medical Center, Omaha, NE

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutaminde in Patients with Newly Diagnosed Metastatic Sensitive Prostate Cancer (CTSU: S1216)

 III

Gladys Pierce RN
gladys.pierce@nmhs.org
402-354-5129

Nebraska Methodist Hospital
Omaha

A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients with Intermediate- Risk Prostate Cancer (RTOG 0815)

 III

Gladys Pierce RN
gladys.pierce@nmhs.org
402-354-5129

-------------------------------

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu or

Amy Filler-Katz

------------------------------------

Natasha Wilson, nwilson@mvcc.cc

 402-991-8070 x203

-------------------------

Nebraska Cancer Research Center – Kelly Madcharo – kmadcharo@lmep.com

-------------------------

Saint Elizabeth – Michelle Broman – mbroman@stez.org

Nebraska Methodist Hospital
Omaha; Nebraska Medical Center, Omaha, NE; Missouri Valley Cancer Consortium, Omaha, NE; Nebraska Cancer Research Center/ Lincoln Medical Education Partnership Lincoln, NE; Saint Elizabeth Cancer Institute, Lincoln

 A Randomized Phase III Study of Neo-adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer (CALGB 90203)

 III

Gladys Pierce RN
gladys.pierce@nmhs.org
402-354-5129

-------------------

Natasha Wilson, nwilson@mvcc.cc

 402-991-8070 x203

------------------

Nebraska Cancer Research Center – Kelly Madcharo – kmadcharo@lmep.com

Nebraska Methodist Hospital
Omaha; Missouri Valley Cancer Consortium, Omaha, NE;  Nebraska Cancer Research Center/ Lincoln Medical Education Partnership Lincoln, NE

A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy (RTOG 0534)

*QOL component closed

 III

Gladys Pierce RN
gladys.pierce@nmhs.org
402-354-5129

---------------

Deborah Meyer, RN, BG  (402) 559-6941 dmeyerk@unmc.edu or  Amy Filler-Katz

---------------

Natasha Wilson, nwilson@mvcc.cc

 402-991-8070 x203

----------------

Saint Elizabeth – Michelle Broman – mbroman@stez.org

------------------

Nebraska Cancer Research Center – Kelly Madcharo – kmadcharo@lmep.com

Nebraska Methodist Hospital
Omaha, NE; Nebraska Medical Center, Omaha, NE ; Missouri Valley Cancer Consortium, Omaha, NE; Saint Elizabeth Cancer Institute, Lincoln, NE; ;  Nebraska Cancer Research Center/ Lincoln Medical Education Partnership Lincoln, NE

Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV 3100. (USOR 12002)

 III

Faye Park, fpark@nebraskacancer.com, 402-691-6972

Nebraska Cancer Specialists, Omaha

 **A Phase I/II Clinical Trial of Lenalidomide in Combination with Oral Cyclophosphamide in Patients with Previously Treated Hormone Refractory Prostate Cancer  (NCT01093183)

 I/II

 Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu or

Susan Kruse

 Nebraska Medical Center, Omaha, NE

A Phase 3, Randomized, Double-Blind, Controlled Trial of Cabozantinib (XL184) Vs. Mitoxantrone Plus Prednisone in Men with Previously Treated Symptomatic Castration-Resistant Prostate Cancer (NCT01522443)

 III

 Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu or

Terry Burke

 Nebraska Medical Center, Omaha, NE

Nebraska Oncology Society
c/o Nebraska Medical Association
Sarah Dunbar
Executive Director
233 South 13th Street Suite 1200
Lincoln, NE 68508
sarahd@nebmed.org (email)
402-474-4472 (phone)
402-474-2198 (fax)

Powered by Wild Apricot Membership Software